Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3199213 | 0.96 | CA4 (0.36) | CA4CA2CA1CASP1FAHD1 | |
| Trifluoroacetic Acid SCHEMBL7870567 | 0.92 | — | — | |
| Trifluoroacetic Acid SCHEMBL2828447 | 0.92 | CA4 (0.38) | CA4CA2CA1CASP1FAHD1 | |
| Trifluoroacetic Acid SCHEMBL18797016 | 0.92 | CA4 (0.38) | CA4CA2CA1CASP1FAHD1 | |
| Trifluoroacetic Acid SCHEMBL282294 | 0.92 | — | — | |
| Trifluoroacetic Acid SCHEMBL204190 | 0.92 | CA4 (0.38) | CA4CA2CA1CASP1FAHD1 | |
| Trifluoroacetic Acid SCHEMBL20541013 | 0.92 | CA4 (0.38) | CA4CA2CA1CASP1FAHD1 | |
| Trifluoroacetic Acid SCHEMBL20569660 | 0.92 | CA4 (0.38) | CA4CA2CA1CASP1FAHD1 | |
| Trifluoroacetic Acid SCHEMBL20569310 | 0.92 | — | — | |
| Trifluoroacetic Acid SCHEMBL20571141 | 0.92 | CA4 (0.38) | CA4CA2CA1CASP1FAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701797-A1 | A PRODUCT AND METHOD FOR THICK-WALLED CAPPED GOLD NANOTUBES | AuNano AB (SE) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024225956-A1 | A PRODUCT AND METHOD FOR THICK-WALLED CAPPED GOLD NANOTUBES | LI, YUYANG (SE) | 2024-10-31 | — | — | WO | disclosed |
| US-20240279869-A1 | ELASTIC CONDUCTIVE FIBER AND METHOD FOR PREPARING THE SAME | SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2024-08-22 | — | — | US | disclosed |
| US-20240279870-A1 | METHOD FOR PREPARING ELASTIC CONDUCTIVE FIBER | SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2024-08-22 | — | — | US | disclosed |
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-8425880-B1 | Metal-containing materials for treatment of bacterial conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-23 | — | — | US | disclosed |
| US-20130095184-A1 | Metal-Containing Materials for Treatment of Bacterial Conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009014781-A2 | METAL-CONTAINING MATERIALS FOR TREATMENT OF BACTERIAL CONDITIONS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2009-01-29 | — | — | WO | disclosed |
| US-20080050452-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-28 | — | — | US | disclosed |
| US-20080044491-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-21 | — | — | US | disclosed |
| US-20080014278-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| US-20080014247-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| WO-2008005705-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | SELENOI, TST, SCLY | CA4 4079/4885CA2 3393/4885CA1 3748/4885 |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | SELENOI, TST, GSS | CA4 4062/4885CA2 3743/4885CA1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.